Regulation of cell signalling by uPAR

被引:744
作者
Smith, Harvey W. [1 ]
Marshall, Chris J. [2 ]
机构
[1] McGill Univ, Goodman Canc Ctr, Montreal, PQ H3A 1A3, Canada
[2] Inst Canc Res, Canc Res UK Ctr Cell & Mol Biol, London SW3 6JB, England
关键词
PLASMINOGEN-ACTIVATOR RECEPTOR; EPIDERMAL-GROWTH-FACTOR; INCREASED CYCLOOXYGENASE-2 EXPRESSION; LIGAND-BINDING DOMAIN; FOCAL ADHESION KINASE; GPI-ANCHORED UPAR; UROKINASE-RECEPTOR; IN-VIVO; BREAST-CANCER; DEFICIENT MICE;
D O I
10.1038/nrm2821
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Urokinase-type plasminogen activator receptor (uPAR) expression is elevated during inflammation and tissue remodelling and in many human cancers, in which it frequently indicates poor prognosis. uPAR regulates proteolysis by binding the extracellular protease urokinase-type plasminogen activator (uPA; also known as urokinase) and also activates many intracellular signalling pathways. Coordination of extracellular matrix (ECM) proteolysis and cell signalling by uPAR underlies its important function in cell migration, proliferation and survival and makes it an attractive therapeutic target in cancer and inflammatory diseases. uPAR lacks transmembrane and intracellular domains and so requires transmembrane co-receptors for signalling. Integrins are essential uPAR signalling co-receptors and a second uPAR ligand, the ECM protein vitronectin, is also crucial for this process.
引用
收藏
页码:23 / 36
页数:14
相关论文
共 179 条
  • [1] Electron microscopy of integrins
    Adair, Brian D.
    Yeager, Mark
    [J]. INTEGRINS, 2007, 426 : 337 - +
  • [2] Urokinase receptor and fibronectin regulate the ERKMAPK to p38MAPK activity ratios that determine carcinoma cell proliferation or dormancy in vivo
    Aguirre-Ghiso, JA
    Liu, D
    Mignatti, A
    Kovalski, K
    Ossowski, L
    [J]. MOLECULAR BIOLOGY OF THE CELL, 2001, 12 (04) : 863 - 879
  • [3] Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice
    Almholt, K
    Nielsen, BS
    Frandsen, TL
    Brünner, N
    Dano, K
    Johnsen, M
    [J]. ONCOGENE, 2003, 22 (28) : 4389 - 4397
  • [4] Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice
    Almholt, K
    Lund, LR
    Rygaard, J
    Nielsen, BS
    Dano, K
    Romer, J
    Johnsen, M
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2005, 113 (04) : 525 - 532
  • [5] Andolfo A, 2002, THROMB HAEMOSTASIS, V88, P298
  • [6] Src kinase activation by direct interaction with the integrin β cytoplasmic domain
    Arias-Salgado, EG
    Lizano, S
    Sarkar, S
    Brugge, JS
    Ginsberg, MH
    Shattil, SJ
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (23) : 13298 - 13302
  • [7] Linking integrin conformation to function
    Askari, Janet A.
    Buckley, Patrick A.
    Mould, A. Paul
    Humphries, Martin J.
    [J]. JOURNAL OF CELL SCIENCE, 2009, 122 (02) : 165 - 170
  • [8] Evolving role of uPA/uPAR system in human cancers
    Ass, Kathleen
    Ahmad, Aamir
    Azmi, Asfar S.
    Sarkar, Sarah H.
    Sarkar, Fazlul H.
    [J]. CANCER TREATMENT REVIEWS, 2008, 34 (02) : 122 - 136
  • [9] The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website
    Bamford, S
    Dawson, E
    Forbes, S
    Clements, J
    Pettett, R
    Dogan, A
    Flanagan, A
    Teague, J
    Futreal, PA
    Stratton, MR
    Wooster, R
    [J]. BRITISH JOURNAL OF CANCER, 2004, 91 (02) : 355 - 358
  • [10] Regulation of urokinase receptor proteolytic function by the tetraspanin CD82
    Bass, R
    Werner, F
    Odintsova, E
    Sugiura, T
    Berditchevski, F
    Ellis, V
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (15) : 14811 - 14818